Humacyte went public via a SPAC merger with Alpha Healthcare Acquisition in a $800m deal.

Humacyte, a clinical-stage biotechnology platform company, went public via a SPAC merger with Alpha Healthcare Acquisition, a special purpose acquisition company, in a $800m deal. PIPE investors for the deal include Fresenius Medical Care, OrbiMed, Monashee Investment Management, Alexandria Venture Investments, UBS O’Connor, Morgan Creek Capital, and a number of unnamed health care-focused funds. "Humacyte is poised to make commercial-scale bioengineered tissues a reality for patients. We enter the next phase of our transformation of regenerative medicine as a robust public company, evaluating our first-in-class bioengineered HAVs in numerous indications. We set out with the lofty goal of changing the practice of medicine, and we are closer than ever today thanks to the unwavering commitment of our employees, our partners and our investors," Laura Niklason, Humacyte Founder, President and CEO.